Sonoma Pharmaceuticals (O8Z) Ratios
Sonoma Pharmaceuticals Ratios
DE:O8Z's free cash flow for Q1 2027 was $-651.00K. For the 2027 fiscal year, DE:O8Z's free cash flow was decreased by $-2.00K and operating cash flow was $-649.00K. See a summary of the company’s cash flow.
| Ratios | Mar 26 | Mar 25 | Mar 24 | Mar 23 | Jun 22 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 2.50 | 3.09 | 3.37 | 3.71 | 2.82 |
| Quick Ratio | 1.75 | 2.38 | 2.64 | 2.94 | 2.37 |
| Cash Ratio | 0.50 | 1.31 | 0.84 | 1.03 | 1.27 |
| Solvency Ratio | -0.28 | -0.36 | -0.54 | -0.61 | -0.48 |
| Operating Cash Flow Ratio | -0.81 | -0.02 | -0.64 | -1.66 | -0.73 |
| Short-Term Operating Cash Flow Coverage | -17.72 | -0.40 | -7.42 | -14.27 | -5.26 |
| Net Current Asset Value | $ 1.24M | $ 3.37M | $ 3.94M | $ 5.54M | $ 6.28M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.06 | 0.02 | 0.04 | 0.05 | 0.07 |
| Debt-to-Equity Ratio | 0.27 | 0.07 | 0.10 | 0.11 | 0.16 |
| Debt-to-Capital Ratio | 0.21 | 0.06 | 0.09 | 0.10 | 0.14 |
| Long-Term Debt-to-Capital Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financial Leverage Ratio | 4.51 | 3.10 | 2.40 | 2.03 | 2.17 |
| Debt Service Coverage Ratio | -9.36 | -15.09 | -13.40 | -10.24 | -6.56 |
| Interest Coverage Ratio | 0.00 | 0.00 | 0.00 | 0.00 | -588.70 |
| Debt to Market Cap | 0.06 | 0.08 | 0.12 | 0.07 | 0.04 |
| Interest Debt Per Share | 0.50 | 0.25 | 0.67 | 2.50 | 5.19 |
| Net Debt to EBITDA | 0.67 | 1.83 | 0.56 | 0.67 | 1.06 |
| Profitability Margins | |||||
| Gross Profit Margin | 37.97% | 38.25% | 37.26% | 33.73% | 31.62% |
| EBIT Margin | -12.60% | -20.35% | -36.91% | -34.43% | -46.62% |
| EBITDA Margin | -11.89% | -19.38% | -35.53% | -33.49% | -45.15% |
| Operating Profit Margin | -12.60% | -25.97% | -36.91% | -34.43% | -46.62% |
| Pretax Profit Margin | -17.51% | -20.35% | -39.51% | -39.06% | -42.90% |
| Net Profit Margin | -16.26% | -24.20% | -37.97% | -38.81% | -40.28% |
| Continuous Operations Profit Margin | -16.26% | -24.20% | -37.97% | -38.81% | -40.28% |
| Net Income Per EBT | 92.86% | 118.92% | 96.10% | 99.36% | 93.87% |
| EBT Per EBIT | 138.93% | 78.36% | 107.02% | 113.44% | 92.03% |
| Return on Assets (ROA) | -22.74% | -25.25% | -32.80% | -31.74% | -26.99% |
| Return on Equity (ROE) | -102.58% | -78.37% | -78.78% | -64.57% | -58.48% |
| Return on Capital Employed (ROCE) | -26.96% | -38.66% | -42.65% | -36.52% | -45.19% |
| Return on Invested Capital (ROIC) | -24.05% | -37.57% | -39.14% | -34.40% | -39.24% |
| Return on Tangible Assets | -22.74% | -25.25% | -32.80% | -31.74% | -26.99% |
| Earnings Yield | -88.52% | -127.20% | -173.82% | -77.71% | -23.90% |
| Efficiency Ratios | |||||
| Receivables Turnover | 3.59 | 3.80 | 2.12 | 5.16 | 5.25 |
| Payables Turnover | 6.30 | 9.26 | 13.16 | 10.46 | 5.26 |
| Inventory Turnover | 3.32 | 3.03 | 2.94 | 3.08 | 3.24 |
| Fixed Asset Turnover | 21.41 | 46.24 | 19.56 | 14.65 | 14.37 |
| Asset Turnover | 1.40 | 1.04 | 0.86 | 0.82 | 0.67 |
| Working Capital Turnover Ratio | 2.47 | 1.64 | 1.35 | 1.28 | 1.29 |
| Cash Conversion Cycle | 153.65 | 177.30 | 268.28 | 154.44 | 112.77 |
| Days of Sales Outstanding | 101.58 | 96.13 | 171.80 | 70.73 | 69.57 |
| Days of Inventory Outstanding | 110.01 | 120.59 | 124.21 | 118.61 | 112.56 |
| Days of Payables Outstanding | 57.94 | 39.42 | 27.73 | 34.90 | 69.36 |
| Operating Cycle | 211.59 | 216.72 | 296.00 | 189.34 | 182.14 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -2.34 | -0.07 | -2.64 | -18.13 | -16.01 |
| Free Cash Flow Per Share | -2.45 | -0.14 | -2.66 | -18.92 | -16.53 |
| Dividend Paid and CapEx Coverage Ratio | -20.48 | -1.10 | -141.06 | -22.87 | -31.01 |
| Capital Expenditure Coverage Ratio | -20.48 | -1.10 | -141.06 | -22.87 | -31.01 |
| Operating Cash Flow Coverage Ratio | -4.67 | -0.29 | -3.94 | -7.25 | -3.11 |
| Operating Cash Flow to Sales Ratio | -0.20 | -0.01 | -0.19 | -0.46 | -0.34 |
| Free Cash Flow Yield | -115.00% | -6.18% | -86.82% | -96.87% | -20.61% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -1.13 | -0.78 | -0.58 | -1.29 | -4.18 |
| Price-to-Sales (P/S) Ratio | 0.18 | 0.19 | 0.22 | 0.50 | 1.68 |
| Price-to-Book (P/B) Ratio | 1.16 | 0.62 | 0.45 | 0.83 | 2.45 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -0.87 | -16.18 | -1.15 | -1.03 | -4.85 |
| Price-to-Operating Cash Flow Ratio | -0.91 | -30.88 | -1.16 | -1.08 | -5.01 |
| Price-to-Earnings Growth (PEG) Ratio | 0.03 | 0.02 | 0.01 | 0.06 | 0.22 |
| Enterprise Value Multiple | -0.87 | 0.85 | -0.06 | -0.82 | -2.67 |
| Enterprise Value | 2.03M | -2.35M | 261.54K | 3.66M | 15.25M |
| EV to EBITDA | -0.87 | 0.85 | -0.06 | -0.82 | -2.67 |
| EV to Sales | 0.10 | -0.16 | 0.02 | 0.28 | 1.21 |
| EV to Free Cash Flow | -0.49 | 14.00 | -0.11 | -0.57 | -3.48 |
| EV to Operating Cash Flow | -0.52 | 26.72 | -0.11 | -0.59 | -3.59 |
| Tangible Book Value Per Share | 1.84 | 3.55 | 6.75 | 23.50 | 32.78 |
| Shareholders’ Equity Per Share | 1.84 | 3.55 | 6.75 | 23.50 | 32.78 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.07 | -0.19 | 0.04 | 0.01 | 0.06 |
| Revenue Per Share | 11.60 | 11.51 | 14.01 | 39.10 | 47.60 |
| Net Income Per Share | -1.89 | -2.79 | -5.32 | -15.18 | -19.17 |
| Tax Burden | 0.93 | 1.19 | 0.96 | 0.99 | 0.94 |
| Interest Burden | 1.39 | 1.00 | 1.07 | 1.13 | 0.92 |
| Research & Development to Revenue | 0.12 | 0.13 | 0.15 | 0.02 | 0.01 |
| SG&A to Revenue | 0.39 | 0.52 | 0.00 | 0.00 | 0.00 |
| Stock-Based Compensation to Revenue | 0.01 | 0.02 | 0.04 | 0.05 | 0.03 |
| Income Quality | 1.24 | 0.03 | 0.50 | 1.19 | 0.84 |
Currency in USD
